BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220322
DTEND;VALUE=DATE:20220325
DTSTAMP:20260515T152210
CREATED:20211111T123644Z
LAST-MODIFIED:20211111T123644Z
UID:32053-1647907200-1648166399@www.pharmajournalist.com
SUMMARY:GPCRs - Targeted Drug Discovery Summit
DESCRIPTION:The inaugural GPCRs – Targeted Drug Discovery Summit has been established to tap into new drug discovery opportunities in undrugged and orphaned GPCRs by better understanding the complex signaling GPCR pathway\, leveraging new structural and genetic data as well as\, emerging screening tools and technologies and up and coming modalities. \nDiscover data driven case studies that showcase the challenges\, learnings and takeaways currently being faced by large pharma\, biotech and academia who are innovating their discovery and development approaches to drug a wider spectrum of clinically relevant but poorly characterized or undrugged GPCRs across a broad range of therapeutic areas such as oncology\, age-related diseases and beyond. \nWhether you are looking to harness the power of structural biology tools or emerging technologies\, join fellow directors\, heads and VPs of drug discovery\, structural biology\, and pharmacology at the GPCRs – Targeted Drug Discovery Summit – the most comprehensive and dedicated scientific and networking forum for innovative biopharma and research institutes to seize the therapeutic opportunities of GPCRs. \nTo know more visit: https://ter.li/d9fxmw
URL:https://www.pharmajournalist.com/event/gpcrs-targeted-drug-discovery-summit/
LOCATION:DoubleTree Suites Boston-Cambridge\, 400 Soldiers Field Rd\, Boston\, MA\, 02134\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220322
DTEND;VALUE=DATE:20220325
DTSTAMP:20260515T152210
CREATED:20211214T012807Z
LAST-MODIFIED:20220124T113103Z
UID:32513-1647907200-1648166399@www.pharmajournalist.com
SUMMARY:STING & TLR-Targeting Therapies
DESCRIPTION:The 3rd STING & TLR-Targeting Therapies Summit is coming at a timely inflection point in this field. \nWith multiple TLR agonists moving into the clinic\, STING agonists exposing new challenges\, multiple approvals on the horizon\, and more novel targets & combinations currently undergoing exciting pre-clinical validation than ever before\, this unique and highly anticipated industry-focused meeting will unite experts in innate immunity to overcome the barriers it faces and accelerate clinical breakthrough. \nReturning in-person to the biopharma hub of Boston\, 30+ expert speakers will take you through case-study led presentations\, juicy panel discussions and live Q&A’s\, all tailored to suit your TLR\, STING & other PRR targeting needs. \nGain connections and insights to plan how to optimize the development of your innate immune agonists into the clinic and overcome obstacles that may impede the delivery of more selective\, better-tolerated medicines to improve survival rates in difficult-to-treat cancers. \nTo know more visit: https://ter.li/z3s9wq
URL:https://www.pharmajournalist.com/event/sting-tlr-targeting-therapies/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220401
DTSTAMP:20260515T152210
CREATED:20211130T161037Z
LAST-MODIFIED:20211130T161037Z
UID:32293-1648512000-1648771199@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy for Blood Disorders
DESCRIPTION:In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies\, the 3rd Gene Therapy for Blood Disorders Summit will unite the leading large pharma and innovative biotechs to share essential learnings from across this rapidly evolving field\, enabling you to progress your pipeline to address the significant unmet need in this field. \nFocused specifically on hemophilia\, beta-thallasemia and sickle cell-directed gene therapies and gene editing approaches\, this event is an invaluable opportunity to learn the realities of durability challenges\, understand strategies to guarantee safety at every stage of development and get a head-start in understanding the most promising technologies set to revolutionise the field. \nIncorporating insights from translational\, clinical and commercial industry experts\, as well as leading clinicians actively involved in late-stage trials\, this is your opportunity to investigate the realities of managing immunogenicity for systemically administered gene therapies\, establishing less cytotoxic conditioning regimens for ex vivo approaches and prepare for the commercial reality of launching a gene therapy and ensuring there is widespread patient adoption. \nTo know more visit: https://ter.li/u41qa2
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-for-blood-disorders/
LOCATION:Boston Logan Airport Hotel\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220402
DTSTAMP:20260515T152210
CREATED:20211210T094616Z
LAST-MODIFIED:20211210T094922Z
UID:32479-1648512000-1648857599@www.pharmajournalist.com
SUMMARY:12th World ADC London
DESCRIPTION:12th Annual World ADC London\n29th March – 1st April 2022\nLondon \nThe ADC field is going from strength to strength\, further catalysed in 2021 by the approvals of Zynlonta and Tivdak respectively\, bringing the total number of commercially available ADCs to 11. \nReturning in-person in from 29th March – 1st April\, be part of the 12th Annual World ADC London and reconnect with 400+ of your peers at the forefront of ADC drug development. \nAfter in-depth research with key opinion leaders within the ADC field\, this is your most extensive programme to-date addressing the most pressing challenges facing ADC developers from discovery through to late phase manufacturing. \nTake a look at the brand-new agenda here! \nThe four-streamed\, four-day unrivalled programme with 75+ industry-leading speakers will equip you with the insights and connections to nourish your current pipelines of ADCs\, discover the next generation of non-traditional ADCs\, and confidently define your manufacturing processes. \nRegister now and join the likes of the likes of Daiichi Sankyo\, AstraZeneca\, ADC Therapeutics\, Seagen and many more to work collaboratively to overcome the distinct challenges ADC drug development holds and maximise the therapeutic window of ADCs.
URL:https://www.pharmajournalist.com/event/12th-world-adc-london/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220329
DTEND;VALUE=DATE:20220401
DTSTAMP:20260515T152210
CREATED:20220107T124627Z
LAST-MODIFIED:20220107T124627Z
UID:32748-1648512000-1648771199@www.pharmajournalist.com
SUMMARY:Next Generation Kinase Inhibitors Summit
DESCRIPTION:Celebrating 20 years of FDA approval and high efficacy profiles\, kinase inhibitors have changed the face of oncology treatment. However\, increasing resistance and safety issues limit the success of existing kinase inhibitor classes. \nThe inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and innovating existing programs to produce the next wave of kinase inhibitor drugs which are able to show efficacious and durable clinical response in oncology and beyond. \nBoasting 20+ speakers\, 1 deep-dive workshop and over 3 days of unrivalled content spanning discovery\, R&D and clinical development\, this event is a unique opportunity for your team to identify and target the undruggable\, elevate drug design for improved target selectivity\, overcome the blood brain barrier and rationalize combinations for more durable responses. \nCollaborate with 80+ senior drug developers in March to achieve the next generation of these kinase inhibitor therapies with optimized specificity\, maximal durability to deliver the best clinical outcomes. \nTo know more visit: https://kinase-inhibitors-summit.com/
URL:https://www.pharmajournalist.com/event/next-generation-kinase-inhibitors-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220330
DTEND;VALUE=DATE:20220402
DTSTAMP:20260515T152210
CREATED:20220211T093912Z
LAST-MODIFIED:20220211T094005Z
UID:33197-1648598400-1648857599@www.pharmajournalist.com
SUMMARY:7th Innate Killer Summit 2022
DESCRIPTION:2021 was a game-changing year for the NK cell community. Positive clinical results have forced the field to wake up to the potential of these pioneering approaches. \nSupporting the field since its’ infancy\, the Innate Killer Summit returns for its 7th year as the leading\, industry-defining forum dedicated to advancing the field to achieve clinical success. \nSpanning the current drug development landscape\, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing\, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies. \nGet your copy of the 2022 agenda here. \nJoin over 200 experts to characterize and contrast cell sources\, supercharge combinations\, optimize CMC workflows\, examine expansion protocols for high-quality products at scale\, and move the field towards persistent\, scalable\, and cost-effective innate immune cell therapies. \nPromising unpublished data\, interactive discussion\, and engaging networking opportunities join this exclusive summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.
URL:https://www.pharmajournalist.com/event/7th-innate-killer-summit-2022/
LOCATION:Sheraton San Diego Hotel & Marina\, 1380 Harbor Island Drive\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220404
DTEND;VALUE=DATE:20220408
DTSTAMP:20260515T152210
CREATED:20211109T090819Z
LAST-MODIFIED:20211109T090819Z
UID:32034-1649030400-1649375999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Muscular Disorders Summit
DESCRIPTION:Mitigating Toxicity & Revolutionizing Muscle Targeting \nThe 2nd Gene Therapy for Muscular Disorders Summit will be returning as an in-person event to Boston in April 2022\, to help gene therapy developers targeting muscular disorders to overcome safety and toxicity \nchallenges and effectively translate their programs into the clinic. \nHighlighting AAV and gene editing challenges for Duchenne’s (DMD)\, Limb-Girdle (LGMD)\, Pompe Disease\, X-Linked Myotubular Myopathy and other muscular disorders\, this industry-focused 4-day event will cover:  \n\nOvercoming immunogenicity challenges and mitigate toxicity with high doses\nOptimizing vector and promoter choice and design for more efficient delivery tomuscle targets\nDefining clinically meaningful muscular endpoints to successfully develop and safely deliver the optimal dose to their muscular targets\n\nJoin over 150 fellow industry experts to learn\, share and benchmark yourselves against your competitors\, and overcome the toxicity and dosage challenges hindering the progress of your gene therapy targeting the muscle. \nTo know more visit: https://ter.li/tbbaua
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-muscular-disorders-summit/
LOCATION:Hanson Wade\, Hyatt Regency Boston Downtown\, 1 Ave de Lafayette\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220405
DTEND;VALUE=DATE:20220408
DTSTAMP:20260515T152210
CREATED:20220110T223347Z
LAST-MODIFIED:20220111T091913Z
UID:32756-1649116800-1649375999@www.pharmajournalist.com
SUMMARY:Wet AMD & DME Drug Development Summit
DESCRIPTION:Accelerating the Development of Novel Anti-VEGF\, VEGF-independent Therapies & Drug Delivery Options To Reduce Clinical Burden\, Widen Therapeutic Index & Treatment Options for Non-responders \nThe second edition of the industry-led Wet AMD & DME Drug Development Summit will give comprehensive insight into the current and emerging angiogenesis-\, inflammatory-directed and anti-fibrotic drug development programmes for these three ophthalmic conditions – neovascular age-related macular degeneration (wet AMD)\, diabetic retinopathy (DR) and diabetic macular edema (DME). \nThe 2022 Summit will include interactive presentations and panel discussions\, covering challenging questions for the whole research community such as: \n\nWhat are the future directions for anti-VEGF therapy to increase patient response rates\, prolong treatment durability and reduce clinical burden?\nWhere is the clinical success for targeting VEGF-independent pathways in this multifactorial disease?\nWhat interventions beyond anti-VEGF give treatment options for refractory or not optimally treated patients?\nHow are drug developers using various drug delivery methods – topical\, intravitreal\, suprachoroidal\, port delivery – to expand the therapeutic window?\nHow has optical coherence tomography (OCT) imaging\, including at-home diagnostic testing\, and artificial intelligence-enabled programming personalized wet AMD and DME treatment and supported clinical trials?\n\nAs the only industry-led forum solely dedicated to finding long-lasting therapeutic interventions for wet AMD and DME\, attendees will have the opportunity to review the multiple pathological mechanisms being actively targeted\, identify the latest clinical data from anti-VEGF suppression (antibody fragments\, delivery systems\, bispecific antibodies\, gene therapy)\, combinational approaches\, non- VEGF pathways (integrin and TKI’s) and VEGF-independent (such as targeting plasma kallikrein) therapies. \nMeet the leading ophthalmology drug developers from big pharma\, biotech and academia searching for treatment breakthroughs and actively gathering clinical evidence to demonstrate a favourable benefit/risk ratio for future products to regulators\, clinicians and payers. \nJoin us next April to hear their latest clinical development programs and identify future portfolio strategies for your organisation. \nTo know more visit: https://ter.li/m98rr7
URL:https://www.pharmajournalist.com/event/wet-amd-dme-drug-development-summit/
LOCATION:Embassy Suites by Hilton Boston Logan Airport\, 207 Porter St.\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220407
DTEND;VALUE=DATE:20220408
DTSTAMP:20260515T152210
CREATED:20211208T111909Z
LAST-MODIFIED:20220309T194319Z
UID:32412-1649289600-1649375999@www.pharmajournalist.com
SUMMARY:Purify’22
DESCRIPTION:PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nThe maiden PURIFY’19 edition was a huge hit amongst fellow chromatographers\, steered by our esteemed advisory board. \nPURIFY’19 was attended by 113 delegates across 19 cities\, spread across 51 corporates with 14 speakers and 6 display zones! \nSo\, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more\, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related. \nDownload Brochure
URL:https://www.pharmajournalist.com/event/purify22/
LOCATION:ITC Kohenur\,Hyderabad
ORGANIZER;CN="Custage Marketing Solutions LP":MAILTO:rashi@custage.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220412
DTEND;VALUE=DATE:20220415
DTSTAMP:20260515T152210
CREATED:20220114T093101Z
LAST-MODIFIED:20220114T093101Z
UID:32768-1649721600-1649980799@www.pharmajournalist.com
SUMMARY:LNP Formulation & Process Development Summit
DESCRIPTION:Embrace Technology Innovations to Optimize LNP Formulation\, Alternative LNP Raw Materials\, Process Control to Achieve Seamless Scale-Up\, Compliance & Cost Effectiveness  \nThe inaugural LNP Formulation & Process Development Summit is the industry’s first forum dedicated to bringing together drug developers within the LNP field to share the latest scientific breakthroughs on formulation and process development. Across 3 days\, you will address challenges and seek solutions to help you optimize your formulation to enhance stability\, efficacy\, and better characterization for drug product quality. This is your chance to explore the use of alternative polymer lipids to maximize scalability and moving towards cGMP manufacturing for pipeline progression. \nThe global nanopharmaceutical drugs market\, catalyzed by the success of Pfizer/BioNTech and Moderna’s mRNA vaccines\, is poised to reach US$82.7 billion by 2027. The demand of novel LNP to support the delivery of oligonucleotide and nucleic acid-based therapies is growing at an exponential rate. With the overwhelming possibilities of lipid nanoparticles\, there are key questions on formulation\, process development and scalability that still need to be answered. There has been no better time to join forces and help accelerate the development of truly remedial LNP therapeutics. \nTo know more visit: https://ter.li/8hrml3
URL:https://www.pharmajournalist.com/event/lnp-formulation-process-development-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220419
DTEND;VALUE=DATE:20220422
DTSTAMP:20260515T152210
CREATED:20211206T123933Z
LAST-MODIFIED:20211206T123933Z
UID:32385-1650326400-1650585599@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy Medical Affairs Summit
DESCRIPTION:Transforming Traditional Medical Affairs \nOptimize Medical Affairs Proactive Engagements and Education Initiatives to Successfully Launch the Next Generation of Gene Therapy Products  \nThe 2nd Annual Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role Medical Affairs plays in delivering gene therapies to patients. This is your opportunity to take inspiration from Medical Affairs leaders of the gene therapy world and learn how traditional Medical Affairs approaches are being transformed to meet the unique challenges associated with gene therapy drug development. \nGain actionable insights from first-to-market pioneers\, who will share how to engage effectively with internal clinical\, commercial and regulatory teams as well as external HCPs\, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex\, high priced Gene Therapy products. \nThe summit will provide a dedicated platform that discusses the role and value of Medical Affairs across each of the phases of the gene therapy development cycle. We will delve into the unique challenges encountered when working with gene therapies\, from adapting to the clinical realities of the rare disease space\, to handling long-term follow up and post-launch regulatory scrutiny\, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before. \nTo know more visit: https://ter.li/xciowp
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-medical-affairs-summit/
LOCATION:Westin Boston Seaport Hotel\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220421
DTEND;VALUE=DATE:20220701
DTSTAMP:20260515T152210
CREATED:20220425T094247Z
LAST-MODIFIED:20220519T120013Z
UID:33903-1650499200-1656633599@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:This year CPhI & P-MEC China returns as a SMART event\, combining 2 months of online event with a 3-day in-person event to help you connect for an extended period. \n \n“Virtual Expo Connect”\, to be held from 21st April – 30th June 2022\, is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. \nPowered by PharmaSources.com\, Virtual Expo Connect builds the online platform adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nTo know more visit: https://www.pharmasources.com/vec2022
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect-2/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:Yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220427
DTSTAMP:20260515T152210
CREATED:20211206T115226Z
LAST-MODIFIED:20211206T115226Z
UID:32376-1650844800-1651017599@www.pharmajournalist.com
SUMMARY:SMi’s 9th Annual Conference Pre-Filled Syringes East Coast
DESCRIPTION:SMi’s 9th Annual Conference\nPre-Filled Syringes East Coast\nMain Conference: April 25 – 26\, 2022 | Workshops: April 27\, 2022 \nSheraton Boston Hotel\, Boston\, MA\, USA \nwww.pfsamericas.com/pharmajournalistwl \nSponsors are: SCHOTT\, ZEON \nExhibitors: Owen Mumford Pharmaceutical Services\, PHC Corporation\, POLYPLASTICS- TOPAS\, Weiss-Aug Group \nDevice innovations\, connected delivery and regulatory guidance for advanced parenteral systems \nThe global pre-filled syringes market was valued at $1139.6 million in 2020 and with the rapid growth of the industry\, is expected to grow at a CAGR of 8.95% up to 2027. With that in mind\, the 9th annual Pre-Filled Syringes East Coast conference will bring together leading industry experts representing big pharma and device developers to discuss the key drivers accelerating the expansion of the industry. \nThe past year has seen significant developments in the injectables landscape with the rapid introduction and development of vaccines in response to the pandemic\, updates in regulations including the EU MDR and FDA guidance on bridging studies\, and increasing industry acceptance of connectivity to aid the user experience. As part of SMi’s leading injectable series\, the 2022 conference will provide an exclusive insight into the latest developing technologies for device design\, advances in parenteral device platforms and development\, insights into growing integration of digital health and deep dives into recent case studies on novel delivery systems. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nVisit the website at: www.pfsamericas.com/pharmajournalistwl \nChair for 2022: \nGretchen Vandal\, Sr. Director\, Head of Global Regulatory Affairs – Devices and Combination Products\, Takeda \nGuest FDA Speaker: \n\nJohn Barr Weiner\, Associate Director for Policy and Product Classification Office\, Office of Combination Products FDA\n\n Featured 2022 Speakers Include: \n\nJoyce Zhao\, Associate Director\, Combination Product\, Takeda\nSuzette Roan\, Associate VP and Head of Global Device Regulatory Affairs\, Sanofi US\nChristine lynn lanning\, Distinguished Scientist\, Device Area Leader\, Merck\nHeather l. Guerin\, Associate Director\, Regulatory Affairs – CMC\, JanssenTieming Ruan\, Senior Director of Device Development\, Alexion Pharmaceuticals\nJohn Schalago\, Executive Director\, Senior Global Program Director Regulatory Affairs\, Novartis\nGretchen Piwinski\, Manager\, Combination Product Laboratories\, Regeneron\nMichael Song\, Associate Director\, Takeda\nDeep S Bhattacharya\, Senior Scientist\, Drug Product Development and Design\, Pfizer\n\nBENEFITS OF ATTENDING: \n\nExplore the latest developments in innovative technologies for device design accelerating the path to self-administration\nAssess the evolving regulatory landscape for pre-filled syringes and discuss approaches to work with regulators as guidance is updated\nEngage in panel discussions with industry leaders to navigate the accelerating digital health landscape for combination products and drug delivery systems\nUnderstand the landscape of delivery for novel drug products and key considerations to overcome challenges in CCI\n\nView the full agenda and speaker line-up online: www.pfsamericas.com/pharmajournalistwl \nWho should Attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers\n\nEARLY-BIRD RATES:  \n\nBOOK BY 17th DECEMBER AND SAVE $400\nBOOK BY 31st JANUARY AND SAVE $200\nBOOK BY 28TH FEBRUARY AND SAVE $100\n\nRegistrations can be made on the event website at: www.pfsamericas.com/pharmajournalistwl
URL:https://www.pharmajournalist.com/event/smis-9th-annual-conference-pre-filled-syringes-east-coast/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220428
DTSTAMP:20260515T152210
CREATED:20211217T132942Z
LAST-MODIFIED:20211217T132942Z
UID:32542-1650844800-1651103999@www.pharmajournalist.com
SUMMARY:2nd Chronic HBV Drug Development Summit
DESCRIPTION:With a tight focus on late translational to phase II clinical progress\, the 2nd Chronic HBV Drug Development Summit returns in person as the definitive industry forum to advance combination therapy and achieve functional cure in hepatitis B virus. \nDedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms\, this industry-orientated forum is timely positioned after EASL to reset standards after the latest readouts. \nFrom transformative advances in establishing synergistic combination regimens\, to navigating clinical endpoints and stopping points\, and illuminating the role of immunotherapy to attain durable functional cure\, don’t miss your chance to join the conversation. \nHarness actionable insights across 3 days of exclusive content from 20+ scientific experts including Gilead Sciences\, Vir Biotechnology\, VBI Vaccines\, Altimmune\, Drug Farm\, Replicor and many more to guide your strategic decisions and drive clinical progress. \nJoin us in Boston to forge successful industry collaborations in combination therapy for chronic HBV. \nTo know more visit: https://ter.li/o1utyk
URL:https://www.pharmajournalist.com/event/2nd-chronic-hbv-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220428
DTSTAMP:20260515T152210
CREATED:20211217T154450Z
LAST-MODIFIED:20211217T154530Z
UID:32594-1650844800-1651103999@www.pharmajournalist.com
SUMMARY:Novel Format Conjugates Summit
DESCRIPTION:The inaugural Novel Format Conjugates Summit exclusively focuses on the common challenges across early research and development of next generation Non-Traditional ‘ADCs’\, or alternative format conjugates approaches for oncology and beyond. This meeting delves into the different technologies of these novel-format conjugates\, exploring how conjugation chemistry is affected for different kinds of therapeutic modalities\, and the impact an alternative format ADC has on targeting. \nAs we look to the future of drug development of novel conjugates\, you will get the chance to hear the cutting-edge science accelerating the development of Bispecific ADCs\, Radio-conjugates\, ISACs\, SMDCs\, Probody conjugates\, Liposomal drug conjugates\, Oligonucleotide conjugates and many more. \nEngage in cross-industry discussions and presentations from over 20 expert speakers across 3 unmissable days and equip yourself with the tools to develop novel format ADCs with an improved therapeutic potential so we can bring more drugs to patients of unmet needs. \nTo know more visit: https://ter.li/0811lm
URL:https://www.pharmajournalist.com/event/novel-format-conjugates-summit/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220425
DTEND;VALUE=DATE:20220428
DTSTAMP:20260515T152210
CREATED:20220125T123012Z
LAST-MODIFIED:20220125T123113Z
UID:32954-1650844800-1651103999@www.pharmajournalist.com
SUMMARY:3rd Supply Chain and Logistics for Cell Therapies Summit
DESCRIPTION:Keen to unite with your #celltherapy supply chain community and gain actionable insights for streamlining logistics\, implementing digital platforms and optimizing patient operations to establish a reliable global delivery of cell therapies? \nThen look no further! The 3rd Supply Chain & Logistics for Cell Therapies Summit is back and taking place in-person for the first time this 25-27 April 2022! \nView the full 3-day agenda here: https://ter.li/yp10r2 \n2022 Agenda Overview: \nWith exclusive presentations and interactive talks on key industry challenges\, gain valuable takeaways from leaders in the field from GlaxoSmithKline\, Legend Biotech\, Iovance\, Gamida Cell\, and more. Discuss standardization\, review digital system implementation\, prepare for upscaling and optimize cryopreservation in person with like-minded supply chain professionals all to maximize efficiency and create a patient-centric end-to-end system. \nDownload the full event guide to learn more about our speakers\, agenda topics\, and face-to-face networking opportunities. https://ter.li/yp10r2
URL:https://www.pharmajournalist.com/event/3rd-supply-chain-and-logistics-for-cell-therapies-summit/
LOCATION:Crowne Plaza Boston – Woburn\, an IHG Hotel\, 15 Middlesex Canal Park Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220429
DTSTAMP:20260515T152210
CREATED:20211213T100512Z
LAST-MODIFIED:20220316T101306Z
UID:32486-1650931200-1651190399@www.pharmajournalist.com
SUMMARY:2nd Ligase Targeting Drug Development Summit
DESCRIPTION:Whilst the exploiting of this therapeutic modality surges through biopharma and academia\, it is essential that we unlock the fundamental challenges within this industry\, as this remains a key factor determining success of degraders in the clinic. \n \nThe 2nd Ligase Targeting Drug Development Summit returns to Boston in April again uniting industry frontiers and leading minds\, as together we discuss\, update\, and learn how to successfully hijack ligases for therapeutic application\, and uncover a critical piece of the puzzle in realizing the full potential of this therapeutic approach. \nFilling the gap of an industry-led ubiquitin discussion\, we again provide an unrivalled forum to unite leading biopharmaceutical giants\, alongside key academics\, to share unseen data\, collaborative efforts and discuss next steps to successfully select\, validate and translate E3’s into a viable therapy. \nJoin us in Boston to expand your understanding of the ever-broadening ligases field and the fast-improving chemical biology tools to seize the therapeutic value of Ubiquitin E3 ligases and differentiate your pipelines. \nTo Know more visit: https://ter.li/rm8y7d
URL:https://www.pharmajournalist.com/event/2nd-ligase-targeting-drug-development-summit/
LOCATION:Online\, EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220428
DTSTAMP:20260515T152210
CREATED:20220117T082710Z
LAST-MODIFIED:20220127T121445Z
UID:32823-1650931200-1651103999@www.pharmajournalist.com
SUMMARY:Reuters Events: Digital Health 2022
DESCRIPTION:Join the world’s leading forum for advancing the delivery of digital care \nDigital Health’s deployment has been as fast as it has wide. Overnight it has become the central focus for hospitals\, clinics and health plans across the nation. The result? Workflows are more complicated than ever. We’re failing on patient engagement. And we still lack a clearly defined digital care payment infrastructure. \nNow is the moment to tackle inefficiencies in our use of digital health or risk sub-optimal becoming the new norm. We must not squander the biggest opportunity for the industry’s advancement in half a century. \nThat’s why we’ve created Reuters Events Digital Health – the place where the standard is set by 300+ executives for the delivery of quality virtual\, predictive\, affordable and equitable care. Our world-leading forum is where leaders of health systems\, payers\, policy makers\, pharma and health tech converge to realize the transformative potential of technology in healthcare.
URL:https://www.pharmajournalist.com/event/reuters-events-digital-health-2022/
LOCATION:Mission Bay Resort\, San Diego\, California
ORGANIZER;CN="Reuters Events":MAILTO:jack.tiplady@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220429
DTSTAMP:20260515T152210
CREATED:20220125T093551Z
LAST-MODIFIED:20220125T093551Z
UID:32942-1650931200-1651190399@www.pharmajournalist.com
SUMMARY:5th Neoantigen Summit Europe
DESCRIPTION: The 5th Neoantigen Summit Europe\, the definitive industry meeting for uncovering the full potential of neoantigens in creating individualised neoantigen vaccines is returning in person! \nFrom understanding the latest clinical insights to reviewing vaccines post-COVID\, our 35+ expert speakers and 3-day agenda developed alongside #Vaccibody\, #Gritstonebio\, #Targovax\, #Vaximm\, #Immunetune and #OdimmaTherapeutics will help you advance your pipeline to successfully weaponise neoantigens for anti-tumour treatment. \nJoin 100+ colleagues and take on the next frontier in neoantigen identification and vaccine manufacturing. \nKey speakers include: Agnete Fredriksen\, Chief Innovation & Strategy Officer\, Nykode Therapeutics | Barbara Loesch\, Head of Technology and Innovation\, Medigene |Jessica Matta\, Co-Founder & Chief Executive Officer & Chief Scientific Officer\, Odimma therapeutics | Andrew Allen\, CEO\, Gritstone bio | Peter Sondermann\, CEO\, Tacalyx GmbH |Sijme Zeilemaker\, Chief Executive Officer\, Immunetune \nFind out more in the event guide here: https://ter.li/gulg78 \nVisit the official event website here: https://ter.li/s89k61
URL:https://www.pharmajournalist.com/event/5th-neoantigen-summit-europe/
LOCATION:Leonardo Royal Amsterdam\, Paul van Vlissingenstraat 24\, Amsterdam\, 1096 BK\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220426
DTEND;VALUE=DATE:20220429
DTSTAMP:20260515T152210
CREATED:20220201T115212Z
LAST-MODIFIED:20220201T115212Z
UID:33082-1650931200-1651190399@www.pharmajournalist.com
SUMMARY:6th R&D Sourcing & Procurement Summit in Pharma
DESCRIPTION:We are excited for the 6th Advanced R&D Procurement & Sourcing in Pharma Summit returning to Boston in April\, reuniting senior leaders to share their stories and lessons learned\, and how they implement strategic sourcing to optimize spending and mitigate risks. \nAs the one and only community dedicated to 100+ R&D procurement\, category management\, and sourcing professionals\, this is your must-attend conference in 2022 to benchmark your SOPs against your peers and stay at the forefront of technology to streamline your procurement processes. Leave this meeting with practical tips to drive scientific innovations with sustainability\, optimized spend and strengthened vendor relationships! \nYour Unmissable Spotlight Case Studies In 2022: \n\nEstablish robust external supplier relationship models to advance your pipeline development with Betrand Rosier\, Global Procurement Head\, Sanofi\nRebrand procurement to be your scientists’ best business partner with Gerard Cardillo\, Vice President\, Global Procurement\nExplore lessons learned from COVID including strategic investing with Sean Cumbie\, Vice President\, Global Sourcing & Procurement\, NOVAVAX\nDevelop sourcing & procurement strategies at lightspeed with James Tornos\, Vice President\, Sourcing & Enterprise Services – Research\, Development and Medical Procurement\, Pfizer\nDeep-dive into driving D&I initiatives\, both within companies and through supplier diversity initiatives in an exclusive\, interactive workshop led by Manuele Burdese\, Senior Director\, Head of Business Insights & Analytics Strategic Sourcing & Procurement\, Bristol Myers Squibb\, Tom Thattacherry\, Head\, Supplier Diversity\, Genentech\n\nTo find out how you and your team can get involved download your free event guide or get in touch.
URL:https://www.pharmajournalist.com/event/6th-rd-sourcing-procurement-summit-in-pharma/
LOCATION:The Bostonian Boston\, 26 NORTH STREET\, BOSTON\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:monica.mojumder-chan@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220427
DTEND;VALUE=DATE:20220429
DTSTAMP:20260515T152210
CREATED:20220131T115758Z
LAST-MODIFIED:20220131T115758Z
UID:33066-1651017600-1651190399@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference
DESCRIPTION:SMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference\nConference: 27 – 28 April 2022\nWorkshops: 29 April 2022\nBoston\, MA\, USA\nhttp://www.microbiologyeastcoast.com/PJwl \nSponsored by: Bioscience International\, Associates of Cape Cod and Microbiologics \nChaired by: Jim Polarine\, Senior Technical Service Manager\, Head of Microbiology & Sterile Technology\, STERIS Corporation \nHarnessing existing methods and novel tools in microbial control to assure continuity in product quality and patient safety \nSMi’s 5th Annual Pharmaceutical Microbiology East Coast Conference is taking place in Boston on April 27-28\, 2022\, with interactive workshops on April 26\, 2022. \nMicrobiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals\, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches. \nEnsuring the sterility of the finished product continues to be one of the most critical aspects of drug development\, however an array of factors are also sustaining new growth and transformation in this field. The regulatory landscape is changing\, firstly with the preparation of Annex 1\, in addition to increasing requirements pertaining to data integrity. Light is being shed on recent product recalls for mould contamination\, and infection outbreaks serve as a reminder to pay more attention to these overlooked organisms\, as well as considerations towards container closure integrity testing which is being increasingly deployed to block microbe movement. \nOn top of this\, the developing integration of automation and robotics into the manufacturing pipeline\, as well as the increased need for more rapid microbiology methods brought about in part by the surge in ATMPs\, are all highlighting the necessity of the field in Pharma.  \nThis industry is ever expanding\, join leading experts in 2022 to discuss and analyse the latest advances and challenges surrounding Pharmaceutical Microbiology. Network with industry professionals\, discuss revisions in regulatory and guidance documents\, and gain a deeper insight into this corner of the field.\nEvent Hashtag: #SMiPharmaMicroEC  \nKey Highlights for 2022:  \n\nReview implementation guidance and validation for efficient disinfectant efficacy programs\nUncover principles in best-practice and the benefits of a robust contamination control strategy\nAddress fungal mould contamination and risk-based tools to tackle spore spreading\nDelve into the sterility assurance assessment and holistic closure integrity testing\nExplore the impact of the ongoing pandemic and the changing face of the pharma industry\nUnderstand new unique case studies\, from contamination control as it relates to microbiome products\, to risk-based assessments of traditional microbiological tests\n2 Interactive Pre-Conference Workshops on April 26\, 2022\n\nInteractive Workshops: \nWorkshop A: Risk Assessment and Cleaning Validation \nWorkshop Leader: Fred Ohsiek\, SME\, Cleaning Validation\, North America \nWorkshop B: USP Microbiology 2022 – Keeping Up with Standards \nWorkshop Leader: Donald Singer\, Chair\, General Chapters – Microbiology Expert Committee\, US Pharmacopeia and Ecolab Life Sciences \nView the full agenda: http://www.microbiologyeastcoast.com  \nWHO SHOULD ATTEND? \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist\, Drug Substance External Manufacturer\, QC Scientists\, Heads of Quality\, Business Development Manager\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist
URL:https://www.pharmajournalist.com/event/smis-5th-annual-pharmaceutical-microbiology-east-coast-conference/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220504
DTEND;VALUE=DATE:20220506
DTSTAMP:20260515T152210
CREATED:20220131T112354Z
LAST-MODIFIED:20220131T112354Z
UID:33057-1651622400-1651795199@www.pharmajournalist.com
SUMMARY:SMi’s 22nd Annual Pain Therapeutics Conference
DESCRIPTION:SMi’s 22nd Annual Pain Therapeutics Conference\nConference 4 – 5 May 2022\nWorkshop: 6 May 2022\nLondon\, UK\nhttp://www.pain-therapeutics.co.uk/PJwl\nSponsored by: CHDR \nConference Chairman: Richard Malamut\, Chief Medical Officer\, Collegium Pharmaceutical\, Inc \nNovel Compounds and Treatments for Pain: Opioids and the Alternatives  \nSMi’s 22nd Pain Therapeutics Conference will cover the leading advances in pain therapeutics\, exploring late development clinical trials\, novel treatments for chronic conditions\, technology collaboration treatments\, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the latest advancements in the field\, highlighting the use of opioids and the future for cannabinoids within the pain therapeutics field. Furthermore\, policy experts will provide an essential regulatory perspective for this year’s agenda\, providing an exciting and comprehensive insight into the pain therapeutics market. \nThe global Postoperative Pain Therapeutics Market was valued at USD 11.26 Million in 2018 and is projected to reach USD 15.87 Million by 2026\, growing at a CAGR of 4.40 % from 2019 to 2026. \nThe pain industry was affected by Covid-19\, with many individuals suffering with pain conditions\, unable to get help or treatment. Therefore\, there has been a push to ensure that new and more effective treatments will be made available to patients. There is also still a need to move away from opioid based pain treatment. \nJoin Europe’s leading Pain Therapeutics Conference in May 2022 to explore new case studies and regulatory perspectives as well as uncover challenges and successes of both pre-clinical and clinical Pain R&D development to equip you with the necessary knowledge to advance R&D in the pain therapeutics industry. \nEvent hashtag: #SMiPain \nKey Reasons to Attend the Conference: \n\nDiscover the new treatments available for those with pain diseases\, such as migraine\, atopic dermatitis and muscle spasms\nDevelop your knowledge of analgesics for the treatment of pain\nDiscuss the new alternative treatments for pain and the use of opioids within the field\nNetwork with industry professionals and discuss recent advances in the industry\n\nView the full agenda: http://www.pain-therapeutics.co.uk/PJwl \nWho Should Attend? \nChief Executive Officer\, Chief Scientific Officers\, Chief Medical Officers\, Managing Directors\, CEO\, Head of Department\, Principal Research Scientists\, Clinical lead\, Clinical Operations in the following fields: \n\nPain and Migraine\nInflammation\nChronic Pain\nNeuropathic Pain\nAnalgesic pre-clinical development\nAnaesthesia and Pain Management\nCNS clinical trials\nIon Channel Pharmacology\nPharmacology Intelligence\nTranslational science\nDrug development\nExploratory development\n\nWorkshop: Friday 6 May 2022\nMolecular and Cellular Pathophysiology of Pain Resolution \nWorkshop Leaders: \nLuda Diatchenko\, Canada Research Chair in Human Pain Genetics\, Department of Anesthesia\, Faculty of Medicine\, McGill University \nJulio Reinecke\, Chief Scientific Officer and Co-Founder\, Orthogen \nPeter Wehling\, CEO and Founder\, Orthogen \nRu-Rong Ji\, Professor in Anesthesiology\, Distinguished Professor of Anesthesiology\, Professor in Neurobiology\, Professor in Cell Biology\, School of Medicine\, Duke Neurobiology
URL:https://www.pharmajournalist.com/event/smis-22nd-annual-pain-therapeutics-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220509
DTEND;VALUE=DATE:20220511
DTSTAMP:20260515T152210
CREATED:20220124T115213Z
LAST-MODIFIED:20220124T115300Z
UID:32925-1652054400-1652227199@www.pharmajournalist.com
SUMMARY:SMi’s 6th Annual Highly Potent Active Pharmaceutical Ingredients
DESCRIPTION:SMi’s 6th Annual Highly Potent Active Pharmaceutical Ingredients \nConference: 9 – 10 May 2022\nLondon\, UK\nWebsite: www.highlypotentapi.com/WLPJ \nChaired by Justin Mason-Home\, Owner\, Director\, HPAPI Project Services Limited  \nEnsuring Risk-Based\, Safety-Driven\, High-Quality Operation \nSMi is proud to present its 6th Annual Highly Potent Active Pharmaceutical Ingredients\, taking place on the 9 – 10 May 2022. \nThe Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027\, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs\, along with the increase in associated toxicities\, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. \nSMi Group are delighted to announce the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference will be taking place on 9th – 10th May 2022 in London\, UK. The conference will encompass the critical topics including risk assessment\, occupational toxicology\, engineering controls for containment\, facility design\, and the impact of pharmaceutical manufacture on the environment. \nBenefits of Attending the HPAPI Conference: \n\nDissect comprehensive hazard assessment and occupational exposure limit determination\nEvaluate the increasing trend toward more potent therapies and the consequences of the changing face of pharma\nAssess engineering containment controls\, from isolators and barriers to fully automated lines\nExplore the employment of cleaning validation\, organisational controls\, and facility as key measure to tackle cross contamination\n\nThis two-day conference offers you peer-to-peer networking with industry experts including heads and directors of EHS\, Occupational Hygiene\, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event\, including key regulatory updates\, and leading case studies from leading pharmaceutical and biotechnology companies. \nEarly Birds: \n\nRegister by 31st January to save £400\nRegister by 28th February to save £200\nRegister by 31st March to save £100\n\nEvent Hashtag: #SMiHPAPi
URL:https://www.pharmajournalist.com/event/smis-6th-annual-highly-potent-active-pharmaceutical-ingredients/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220509
DTEND;VALUE=DATE:20220512
DTSTAMP:20260515T152210
CREATED:20220222T100531Z
LAST-MODIFIED:20220222T100531Z
UID:33327-1652054400-1652313599@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences West 2022
DESCRIPTION:LEAP HR: Life Sciences West is your best opportunity to hear how scaling life sciences organizations are implementing the experimental people strategies required to drive innovation and growth whilst operating in a tight talent market. \nStep inside 30+ case studies of the radical\, future-focused HR thinking that will empower you to transform your impact and turbocharge scale and innovation in biotech\, pharma and medical devices organizations. \nGain access to the HR innovation that is truly making a difference to employees\, patients and customers – and leave with a brand-new playbook for the people function to thrive in the fast-paced operating environments of life sciences organizations on the West Coast and surrounding areas. \nWith a world-class speaker faculty from leading life sciences organizations such as: Atara Biotherapeutics\, Gilead Sciences\, BridgeBio\, Assembly Biosciences\, Revolution Medicines\, 10X Genomics and many more. \nWhether your business is rapidly growing\, undergoing serious transition or quickly evolving\, LEAP HR: Life Sciences West is your opportunity to plug into a ready-made network of peers who have already solved the talent challenges you’re facing in a candidate-led talent market on the tech-hub West Coast and surrounding areas. \nTo know more visit: https://bit.ly/3h3w3Nt
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-west-2022/
LOCATION:Marriott La Jolla\, 4240 La Jolla Village Dr\, La Jolla\, CA\, 92037\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220510
DTEND;VALUE=DATE:20220513
DTSTAMP:20260515T152210
CREATED:20220105T163123Z
LAST-MODIFIED:20220106T100246Z
UID:32667-1652140800-1652399999@www.pharmajournalist.com
SUMMARY:Adenosine-Pathway Targeted Cancer Immunotherapy Summit
DESCRIPTION:Adenosine-pathway therapies have produced a plethora of promising clinical trial data that is being met with refreshed excitement\, enthusiasm\, and R&D investment for adenosine-pathway targets. \nWith reinvigorated confidence in the field\, join fellow industry and academic thought leaders at the inaugural Adenosine-Pathway Targeted Cancer Immunotherapy Summit. This is the only comprehensive forum dedicated to optimizing efficacy of adenosine-pathway targeted drugs\, overcoming challenges of resistance and immunosuppression and supercharging therapeutics to patients in need. \nFrom analyzing the latest developments in understanding adenosine signaling in the TME\, to rationalizing drug combinations that enhance patient responses\, and exploring tools that quantify adenosine to select patients\, this is the one-stop-shop event for all things adenosine-pathway. \nHarness cutting-edge insights across 3 days of exclusive content from industry heavyweights including Astrazeneca\, Takeda\, Corvus Pharmaceuticals\, iTeos Pharmaceuticals\, Domain Therapeutics and more. Leave this definitive conference equipped with novel ideas\, actionable lessons learned and new connections enabling you to progress your adenosine-pathway targeted cancer immunotherapies to the clinic. \nTo know more visit: https://ter.li/q8tgbz
URL:https://www.pharmajournalist.com/event/adenosine-pathway-targeted-cancer-immunotherapy-summit/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220510
DTEND;VALUE=DATE:20220513
DTSTAMP:20260515T152210
CREATED:20220207T093750Z
LAST-MODIFIED:20220207T093750Z
UID:33162-1652140800-1652399999@www.pharmajournalist.com
SUMMARY:7th Annual 3D Tissue Models Summit 2022
DESCRIPTION:Integrate Advanced 3D Models with Scalability & Predictability to Supercharge Your Modeling Toolbox & Enhance Clinical Confidence \nFollowing the FDA’s announcement of ‘Alternative Methods Working Group’ in the summer\, 2021\, Roche’s newly opened pRED Innovation Center in Basel\, and exciting data from Recce Pharma’s anti-infective candidate using organoids\, the 7th Annual 3D Tissue Models Summit will return to Boston in May 2022 to reunite the community of drug discovery and development experts. This is the definitive meeting for drug developers to explore and integrate complex 3D models featuring 30+ real-life case studies across 2 dedicated tracks and their lessons learned. \nJoin us in May to stay ahead of the curve and through 30+ real-life case studies\, you will learn and meet trailblazers in 3D models to revolutionize your drug discovery and development protocols\, giving you greater confidence in clinical relevancy and accelerating novel treatments to patients in a safe and affordable manner! \nTo know more visit: https://ter.li/oly672
URL:https://www.pharmajournalist.com/event/7th-annual-3d-tissue-models-summit-2022/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220510
DTEND;VALUE=DATE:20220513
DTSTAMP:20260515T152210
CREATED:20220216T112754Z
LAST-MODIFIED:20220216T112754Z
UID:33261-1652140800-1652399999@www.pharmajournalist.com
SUMMARY:3rd Manufacturing Engineering & Facility Management in Pharma Summit
DESCRIPTION:Following innovative technological breakthroughs and the FDA’s Emerging Technology Program\, the pharmaceutical industry is experiencing a renaissance period with an unprecedented level of investments in new builds and next-generation technology to support novel pipeline progression. \nThe ability to commission a modern\, flexible\, compliant facility on time and a budget have never been so critical to drug developers and patients worldwide. \nThe 3rd Manufacturing Engineering & Facility Management in Pharma Summit is the industry’s first definitive discussion and networking forum designed to reunite leaders in the manufacturing and facilities fields in person after two years to share scientific breakthroughs and address challenges the industry is facing. With the pharmaceutical industry entering Pharma 4.0\, technology advances and facilities designs must adapt to a digital\, remote world to enhance tomorrow’s CGT pipeline. \nDesigned alongside the likes of Bayer\, AstraZeneca\, and Catalent\, this industry-focused forum allows you to discuss novel cutting-edge technologies\, the latest approaches of engineering modular\, flexible facilities and address the supply chain crisis. \nWith 22+ hours of content\, 3 interactive workshops\, and over 2 hours of networking with key industry leaders\, this comprehensive forum will uniquely combine leaders in the manufacturing\, engineering\, and facilities fields in one setting to share lessons learned\, case studies\, and advancements in the field. \nJoin 80+ of your peers and be part of this unique opportunity to engage in cross-industry discussions and presentations from 20+ expert speakers on sharing technology innovations that are transforming the manufacturing field\, maximizing productivity and capital efficiency through excellent engineering and facility management\, and collaborating with stakeholders to ensure on-time\, on-budget commissioning\, and validation. \nJoin us this May to maximize your facility flexibility\, asset lifespan\, productivity & compliance through excellent engineering\, robust validation & technology adoption! \nTo know more visit: https://ter.li/qe5ezy
URL:https://www.pharmajournalist.com/event/3rd-manufacturing-engineering-facility-management-in-pharma-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220511
DTEND;VALUE=DATE:20220513
DTSTAMP:20260515T152210
CREATED:20220207T100435Z
LAST-MODIFIED:20220207T100435Z
UID:33172-1652227200-1652399999@www.pharmajournalist.com
SUMMARY:Injectable Drug Delivery Conference 2022
DESCRIPTION:SMi Group Introduces the 4th Annual…  \nInjectable Drug Delivery Conference 2022 \n11th May to 12th May 2022\, \nLondon\, United Kingdom \nwww.injectable-drug-delivery.com/ \nInnovations in Formulation and Device Design for Enhanced Subcutaneous Delivery \nAs Part of Europe’s leading Injectable conference series\, we will assess innovations in drug product formulation and biologics\, new technologies in device design and the use of long-release injectable compounds. \nThere is a rising demand for vaccines\, insulin\, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route\, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027. \nThis year’s event will highlight the significance of sustainability within the injectable drug delivery industry\, whilst also providing regulatory insight on the changes that have occurred. There will be an additional focus on the impact that covid has had on the success within this industry over the past year. The conference will also highlight successes within the industry and the formulation challenges of long-lasting\, highly viscous and high-volume drug delivery. \nThe benefits of attending: \n\nDiscover the new technologies and latest injectable devices being used within the industry\nDevelop your understanding of high-volume and long-acting injectable compounds\nExplore the sustainable possibilities that can be adapted within the industry for a green future\nDelve into the world of biologics and biosimilars and what these mean for the injectable drug market\nNetwork with key industry leaders and discover the leading companies within the injectables space\n\nWho should attend: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers\, Scientists\, Researchers of: \n\nAutoinjectors\nWearables\nDevice Engineering\nHuman Factors\nCMC\nInjectables\nSterile Manufacturing\nPackaging\nRegulatory Affairs\n\nFeatured Speakers: \n\nAlexander Zuern\, Device testing manager\, Novartis International AG\nAndrew Warrington\, Project Leader & Patient Advocate\, Novartis\nBenjamin Werner\, Scientist\, Boehringer Ingelheim Pharma GmbH & Co. KG\nBjorg K Hunter\, Regulatory Manager\, Devices\, GSK\nBlake Green\, Senior Manager Regulatory Affairs\, Amgen\nCamille Dagallier\, Formulation and Drug Process Development Senior Scientist\, Sanofi\nChristopher Muenzer\, Senior Device Technology Manager\, Novartis\nJoel Richard\, Head of Technical & Pharmaceutical Operations\, MedinCell\nMark Palmer\, Scientific Leader\, Biopharm Device Engineering\, GSK\nRebecca Moses\, Director\, Core Human Factors Inc.\nRupal Nguyen\, Principal Engineer\, Allergan\nStefania Ragone\, Pharmaceutical Assessor\, Medicines & Healthcare Products Regulatory Agency (MHRA)\nTina Arien\, Principal Scientist\, Janssen Pharmaceutica\nVikas Jaitely\, Director\, Global Regulatory Affairs Transitional Medicine and Devices\, Merck\n\nPast attendees have included \nAdvanz Pharma; Amgen; AstraZeneca; BD – Becton Dickinson; Bd Medical-Pharmaceutical Systems; BD Technologies and Innovation; Becton Dickinson; Boehringer Ingelheim GmbH & Co. KG; Boehringer Ingelheim Pharma GmbH & Co. KG; BSI Group; Chugai Pharmaceutical CO. LTD.; Congenius; Core Human Factors; F Hoffmann -La Roche Inc; GlaxoSmithKline; Glenmark Pharmaceuticals Inc.; GSK; Haselmeierá; Haughton Design Ltd; Ipsen Biopharm Limited; Janssen Pharmaceutica; Janssen Pharmaceutica NV; Legacy Allergan/AbbVie; LEO Pharma A/S; MedinCell; Merck; Merck Connected Health & Devices; MHRA; Micropore Technologies Ltd; Novartis / DD&C; Novartis International AG; Novo Nordisk Pharma; Owen Mumford; Pfizer UK Limited; Raumedic AG; Roche; SABIC; Sabic SHPP; Sandoz – A Novartis Company; Sanofi; Sanofi SWI; Team Consulting; Teva Pharamceuticals; UCB; Vetter Pharma-Fertigung GmbH & Co. KG; Zealand Pharma A/S \nAdditional Contact Info: \nT: +44 (0)20 7827 6088 \nE: rjones@smi-online.co.uk \nLinkedIn: @SMi Pharma \nTwitter: @SMiPharm #SMiInjectables
URL:https://www.pharmajournalist.com/event/injectable-drug-delivery-conference-2022/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:rjones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220517
DTEND;VALUE=DATE:20220520
DTSTAMP:20260515T152210
CREATED:20220106T133126Z
LAST-MODIFIED:20220106T133728Z
UID:32678-1652745600-1653004799@www.pharmajournalist.com
SUMMARY:4th Microbiome Movement - Maternal & Infant Health Summit 2022
DESCRIPTION:The 4th Microbiome Movement - Maternal & Infant Health Summit is returning\, in person\, on May 17-19\, 2022 with the goal of uniting expert industry and academic minds to tackle the biggest challenges in the understanding\, targeting and treatment creation for the maternal and infant microbiome. \nThis summit is the only place where you will find such a collaborative and engaged group of speakers and attendees with a diverse group of backgrounds in academia\, drug discovery\, nutritional product creation and clinical health care – you can be sure to hear a wide range of opinions and perspectives. \nEnsure you do not miss out on the latest and greatest work in fields relating to the microbiome such as maternal health\, the vaginal microbiome\, harnessing the microbiome for preventative treatment\, breastmilk\, pre-term birth and infant allergic/metabolic disease. \nTo know more visit: https://ter.li/81ntsl
URL:https://www.pharmajournalist.com/event/4th-microbiome-movement-maternal-infant-health-summit-2022/
LOCATION:DoubleTree by Hilton Hotel Boston – Bedford Glen\, 44 Middlesex Turnpike\, Bedford\, MA\, 01730\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@microbiome-movement.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220517
DTEND;VALUE=DATE:20220520
DTSTAMP:20260515T152210
CREATED:20220114T102623Z
LAST-MODIFIED:20220209T111249Z
UID:32776-1652745600-1653004799@www.pharmajournalist.com
SUMMARY:Pharma Clinical 2022
DESCRIPTION:The pandemic response has accelerated technology adoption in clinical trials\, but we have neglected patient needs by failing to develop co-created\, data-driven\, standardised and accountable trial designs.  \nIn the face of rethinking clinical strategy\, our mission is clear: it’s time to develop a better system. We must establish new industry-wide benchmarks now\, leverage recent digital innovations\, and ensure permanent cultural change toward patient- centric trials. If we do not act immediately\, we risk losing this opportunity to rebuild patient trust.    \nThis is why we are bringing together the world’s clinical leadership at Reuters Events: Pharma Clinical 2022 (May 17-19\, Virtual). We aim to define the new standards in digital and patient innovation for clinical transformation. Join 500 + clinical innovators and 40 + expert speakers to create an accountable clinical ecosystem where patient diversity\, centricity and empowerment aren’t just slogans – they are core principles.    \nTo know more visit: https://bit.ly/3npeUkP
URL:https://www.pharmajournalist.com/event/pharma-clinical-2022/
LOCATION:Virtual
ORGANIZER;CN="Reuters Events":MAILTO:usmaan.khan@thomsonreuters.com
END:VEVENT
END:VCALENDAR